Marcel Nijland
dr.
I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.
Tumour necrosis as assessed with F-18-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements
Published in: European Radiology
Access to document
10.1007/s00330-019-06178-9
document
OBJECTIVES: MYC gene rearrangements in diffuse large B cell lymphomas (DLBCLs) result in high proliferation rates and are associated with a poor prognosis. Strong proliferation is associated with high metabolic demand and tumour necrosis. The aim of this study was to investigate differences in the presence of necrosis and semiquantitative 18F-FDG PET metrics between DLBCL cases with or without a MYC rearrangement. The prognostic impact of necrosis and semiquantitative 18F-FDG PET parameters was investigated in an explorative survival analysis. METHODS: Fluorescence in situ hybridisation analysis for MYC rearrangements,...
Xaver U Kahle, Menno Hovingh, Walter Noordzij, Annika Seitz, Arjan Diepstra, Lydia Visser, Anke van den Berg, Tom van Meerten, Gerwin Huls, Ronald Boellaard, Thomas C Kwee, Marcel Nijland
Characterization of post-transplant lymphoproliferative disorder with semi-quantitative FDG-PET/CT
Aim/Introduction: One of the most dire complications of hematopoietic stem cell (HSCT) and solid organ transplantation (SOT) is the development of post-transplant lymphoproliferative disorder (PTLD). PTLD compromises a broad spectrum of disorders classified by the 2017 World Health Organization (WHO) in non-destructive, polymorphic, monomorphic and classic Hodgkin lymphoma. Distinct morphologies are associated with a more favorable clinical course and better response to initial treatment. Reduction of immunosuppression, commonly used as first-line treatment, has been associated with higher response rates in non-destructive and polymorphic PTLD, while a more aggressive...
F. Montes De Jesus, W. Noordzij, X. Kahle, M. Nijland, E. Verschuuren, R. Dierckx, T. Van Der Meerten, W. Van Der Bij, G. Huls, T. Kwee, A. Glaudemans
CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL
Published in: Cancer immunology research
Access to document
10.1158/2326-6066.CIR-18-0781
document
Addition of rituximab (R) to “CHOP” (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy improved outcome for diffuse large B-cell lymphoma (DLBCL) patients. Approximately 40% of patients who receive R-CHOP still succumb to disease due to intrinsic resistance or relapse. A potential negative regulator of DLBCL treatment outcome is the CD47 “don’t eat me” immune checkpoint. To delineate the impact of CD47, we used a clinically and molecularly well-annotated cohort of 939 DLBCL patients, comprising both germinal center B-cell (GCB) and non-GCB DLBCL subtypes, treated with either CHOP or R-CHOP....
Renee Bouwstra, Yuan He, Janneke Willemien de Boer, Hilde Kooistra, Ewa Cendrowicz, Rudolf S N Fehrmann, Emanuele Ammatuna, Christine Eulenburg, Marcel Nijland, Gerwin Huls, Edwin Bremer, Tom van Meerten
Responsevaluatie bij posttransplantatielymfomen door middel van F-FDG-PET/CT en circulerend tumor-DNA (MRD-PTLD)
Relationship between semiquantitative 18F-fluorodeoxyglucose positron emission tomography metrics and necrosis in classical Hodgkin lymphoma
Published in: Scientific Reports
Access to document
10.1038/s41598-019-47453-5
document
Semiquantitative 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG PET) parameters have been proposed as prognostic markers in classical Hodgkin lymphoma (cHL). In non-Hodgkin lymphoma necrosis as assessed by 18F-FDG PET or computed tomography (CT) (necrosisvisual) correlates with an adverse prognosis. We investigated whether semiquantitative 18F-FDG PET metrics correlate with necrosisvisual, determined the incidence of necrosisvisual and explored the prognostic impact of these factors in cHL. From 87 cHL cases treated with ABVD, (escalated) BEACOPP or CHOP chemotherapy between 2010 and 2017, 71 had both a NEDPAS/EARL accredited 18F-FDG PET and...
X U Kahle, F M Montes de Jesus, T C Kwee, T van Meerten, A Diepstra, S Rosati, A W J M Glaudemans, W Noordzij, W J Plattel, M Nijland